J.P. Morgan Healthcare Conference

January 9, 2024

NEUROCRINE® BIOSCIENCES

You Deserve Brave Science®

Safe Harbor Statement

In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; our financial and operating performance, including our future revenues, expenses, or profits; our collaborative partnerships; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: our future financial and operating performance; risks and uncertainties associated with the commercialization of INGREZZA; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with U.S. federal or state legislative or regulatory and/or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue; risks associated with potential generic entrants for our products; and other risks described in our periodic reports filed with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Neurocrine Biosciences disclaims any obligation to update the statements contained in this presentation after the date hereof.

Our Vision

You Deserve *Brave* Science®

1. UNDERSTANDING THE BRAIN TO TREAT THE BODY
2. RELIEVING PATIENT SUFFERING
3. TAKING RESPONSIBILITY BEYOND MEDICINE

NEUROCRINE® BIOSCIENCES

Our Purpose

Relieve suffering for people with great needs, but few options

Multiple Commercial Products

In the U.S.

INGREZZA® * (valbenazine) capsules

TARDIVE DYSKINESIA

CHOREA-HUNTINGTON'S DISEASE

Orilissa® ‡ elagolix tablets 150 mg 200 mg

ENDOMETRIOSIS

Oriahnn® ‡ elagolix, estradiol and norethindrone acetate capsules and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg

UTERINE FIBROIDS

In the U.S. and Europe

Alkindi® hydrocortisone granules in capsules for opening

ADRENAL INSUFFICIENCY

In Europe

Efmody® Hydrocortisone modified-release hard capsules

CONGENITAL ADRENAL HYPERPLASIA

NEUROCRINE® BIOSCIENCES

*Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets
†Under license from Bial
‡AbbVie has global commercialization rights

Well-positioned for sustained and long-term growth

Commercial

INGREZZA® (valbenazine) capsules

TD AND HD CHOREA

$1.82B - $1.84B 2023 Annual Net Sales Guidance

~600,000 Affected by Tardive Dyskinesia (TD) in the U.S.; **65%** are undiagnosed

~90% of the 41,000 People in the U.S. Diagnosed with Huntington Disease Will Develop Chorea

R&D Focus

- Neurology
- Neuroendocrinology
- Neuropsychiatry

Robust Pipeline

Multiple Compounds in Mid- to Late-Stage Studies

Rapidly Growing Early-Stage Portfolio

Strong Financial Position

~$1.5B

Cash and Investments as of 9/30/2023

Strong Balance Sheet

Durable Cash Flows

Attractive P&L Profile

NEUROCRINE® BIOSCIENCES

*Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets

Where Are We Today?

- **Discovered and Developed** Three Novel FDA-Approved Programs
- **Deep Expertise** in Neuroscience Drug Development
- **Fully-Integrated Organization** with Both R&D and Commercial Capabilities
- **Growing Blockbuster** Commercial Product in INGREZZA with Strong IP Protection
- **Future Blockbuster Opportunity** with Crinecerfont
- **Largest Portfolio of Muscarinic Compounds** in Clinical Development
- **Strong Financial Profile** That Can Support Significant R&D Investment

Building a Leading Neuroscience-Focused Company

NEUROCRINE® BIOSCIENCES

Building and Maximizing the Pipeline

of Programs by Stage

Phase 1	Phase 2	Phase 3	NDA
5	8	4	1



NEUROCRINE BIOSCIENCES

* Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets

† Sosei Heptares has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events

In-licensed program =
(1) Sosei Heptares (2) Idorsia Ltd (3) Xenon Pharmaceuticals Inc (4) Sanofi
(5) Takeda Pharmaceutical Company Ltd
Neurocrine Biosciences has global rights unless otherwise noted.

Building and Maximizing the Pipeline

of Programs by Stage

Phase 1	Phase 2	Phase 3	NDA
5	8	4	1



NEUROCRINE BIOSCIENCES

* Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets

† Sosei Heptares has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events

In-licensed program =
(1) Sosei Heptares (2) Idorsia Ltd (3) Xenon Pharmaceuticals Inc (4) Sanofi
(5) Takeda Pharmaceutical Company Ltd
Neurocrine Biosciences has global rights unless otherwise noted.

Building and Maximizing the Pipeline

of Programs by Stage

Phase 1	Phase 2	Phase 3	NDA
5	8	4	1



* Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets

† Sosei Heptares has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events

In-licensed program =
(1) Sosei Heptares (2) Idorsia Ltd (3) Xenon Pharmaceuticals Inc (4) Sanofi
(5) Takeda Pharmaceutical Company Ltd
Neurocrine Biosciences has global rights unless otherwise noted.

Building and Maximizing the Pipeline

of Programs by Stage

Phase 1	Phase 2	Phase 3	NDA
5	8	4	1



NEUROCRINE BIOSCIENCES

* Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets

† Sosei Heptares has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events

In-licensed program =
(1) Sosei Heptares (2) Idorsia Ltd (3) Xenon Pharmaceuticals Inc (4) Sanofi
(5) Takeda Pharmaceutical Company Ltd
Neurocrine Biosciences has global rights unless otherwise noted.

NEUROCRINE® BIOSCIENCES

Congenital Adrenal Hyperplasia

Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH)

21OHD CAH Results in:

- Impaired Synthesis of Cortisol and (Often) Aldosterone
- Excess Adrenal Androgen Production

Treatment Must Balance Consequences of:

- Supraphysiologic Glucocorticoid (GC) Doses
- High ACTH and Androgen Excess



Adapted from: Han TS et al. *Nat Rev Endocrinol.* 2014;10(2):115-24.

NEUROCRINE BIOSCIENCES

Mallappa A and Merke DP. *Nat Rev Endocrinol.* 2022;43(1):91-159.
ACTH, adrenocorticotropic hormone; GC, glucocorticoids; TARTs, testicular adrenal rest tumors.

Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH)

21OHD CAH Results in:

- Impaired Synthesis of Cortisol and (Often) Aldosterone
- Excess Adrenal Androgen Production

Treatment Must Balance Consequences of:

- Supraphysiologic Glucocorticoid (GC) Doses
- High ACTH and Androgen Excess



Adapted from: Han TS et al. *Nat Rev Endocrinol.* 2014;10(2):115-24.

NEUROCRINE BIOSCIENCES

Mallappa A and Merke DP. *Nat Rev Endocrinol.* 2022;43(1):91-159.
ACTH, adrenocorticotropic hormone; GC, glucocorticoids; TARTs, testicular adrenal rest tumors.

Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH)

21OHD CAH Results in:

- Impaired Synthesis of Cortisol and (Often) Aldosterone
- Excess Adrenal Androgen Production

Treatment Must Balance Consequences of:

- Supraphysiologic Glucocorticoid (GC) Doses
- High ACTH and Androgen Excess



Adapted from: Han TS et al. *Nat Rev Endocrinol.* 2014;10(2):115-24.

NEUROCRINE® BIOSCIENCES

Mallappa A and Merke DP. *Nat Rev Endocrinol.* 2022;43(1):91-159.
ACTH, adrenocorticotropic hormone; GC, glucocorticoids; TARTs, testicular adrenal rest tumors.

Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD CAH)

21OHD CAH Results in:

- Impaired Synthesis of Cortisol and (Often) Aldosterone
- Excess Adrenal Androgen Production

Treatment Must Balance Consequences of:

- Supraphysiologic Glucocorticoid (GC) Doses
- High ACTH and Androgen Excess

Reduced GC Dosing **crinecerfont** Androgen Control



Adapted from: Han TS et al. *Nat Rev Endocrinol.* 2014;10(2):115-24.

Mallappa A and Merke DP. *Nat Rev Endocrinol.* 2022;43(1):91-159.
ACTH, adrenocorticotropic hormone; GC, glucocorticoids; TARTs, testicular adrenal rest tumors.

Key Milestones in 2024 and Longer Term

2024

- **April PDUFA for Valbenazine Oral Granules Sprinkle Formulation**
- **Submitting New Drug Application for Crinecerfont in Adult and Pediatric CAH Indications**
- **Advancing Five Phase 1 Programs** including Four Muscarinic Compounds and next generation VMAT2 Inhibitor
- **Anticipating Top-Line Data for Five Phase 2 Programs**
  - Efmody for Adrenal Insufficiency and CAH in 1H
  - NBI-’845 (AMPA Potentiator) for Inadequate Response to Treatment in Major Depressive Disorder in 1H
  - NBI-’568 (M4 Agonist) for Schizophrenia in 2H
  - Luvadaxistat (DAAO Inhibitor) for Cognitive Impairment Associated with Schizophrenia in 2H
- **Developing Sustainable R&D Engine**

Longer Term

- **Anticipated Crinecerfont Approved in U.S. (2025) and in Europe (2026)**
- **Advancement of 2 Gene Therapy Programs Into Clinical Development (2025)**
- **Advancement of 20 Development Candidates (Through 2027)**
- **Sustainable R&D Engine Generating 1-2 Mid-to-Late-Stage Clinical Read-Outs Every Year**
- **Clinical Pipeline**
  - Weighted Towards Neurology vs.2023
  - Balanced Between Biologics and Small Molecules
  - Focused on Clinically and / or Genetically Validated Targets
  - Majority of Candidates Considered “Next” or “Best-In-Class”
- **INGREZZA® (valbenazine) Market Exclusivity Into 2038**

What *Brave* science can mean to patients

NEUROCRINE® BIOSCIENCES

J.P. Morgan Healthcare Conference

January 9, 2024

NEUROCRINE® BIOSCIENCES

You Deserve Brave Science®